Logo image of 88Q.DE

4BASEBIO PLC (88Q.DE) Stock Fundamental Analysis

Europe - Frankfurt Stock Exchange - FRA:88Q - GB00BMCLYF79 - Common Stock

7 EUR
-0.2 (-2.78%)
Last: 12/18/2025, 7:00:00 PM
Fundamental Rating

3

88Q gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 83 industry peers in the Biotechnology industry. 88Q scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. 88Q shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year 88Q has reported negative net income.
In the past year 88Q has reported a negative cash flow from operations.
88Q had negative earnings in each of the past 5 years.
88Q had a negative operating cash flow in each of the past 5 years.
88Q.DE Yearly Net Income VS EBIT VS OCF VS FCF88Q.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

Looking at the Return On Assets, with a value of -39.08%, 88Q is doing worse than 60.24% of the companies in the same industry.
Looking at the Return On Equity, with a value of -75.90%, 88Q is in line with its industry, outperforming 49.40% of the companies in the same industry.
Industry RankSector Rank
ROA -39.08%
ROE -75.9%
ROIC N/A
ROA(3y)-45.31%
ROA(5y)-32.39%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
88Q.DE Yearly ROA, ROE, ROIC88Q.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

The Gross Margin of 88Q (61.55%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of 88Q has declined.
88Q does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 61.55%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.33%
GM growth 5YN/A
88Q.DE Yearly Profit, Operating, Gross Margins88Q.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

More info and screens

5

2. Health

2.1 Basic Checks

88Q does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, 88Q has more shares outstanding
Compared to 5 years ago, 88Q has more shares outstanding
The debt/assets ratio for 88Q has been reduced compared to a year ago.
88Q.DE Yearly Shares Outstanding88Q.DE Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M
88Q.DE Yearly Total Debt VS Total Assets88Q.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

88Q has an Altman-Z score of 1.58. This is a bad value and indicates that 88Q is not financially healthy and even has some risk of bankruptcy.
88Q has a better Altman-Z score (1.58) than 66.27% of its industry peers.
88Q has a Debt/Equity ratio of 0.81. This is a neutral value indicating 88Q is somewhat dependend on debt financing.
88Q's Debt to Equity ratio of 0.81 is in line compared to the rest of the industry. 88Q outperforms 42.17% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.81
Debt/FCF N/A
Altman-Z 1.58
ROIC/WACCN/A
WACC8.39%
88Q.DE Yearly LT Debt VS Equity VS FCF88Q.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

88Q has a Current Ratio of 11.36. This indicates that 88Q is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of 88Q (11.36) is better than 95.18% of its industry peers.
A Quick Ratio of 11.15 indicates that 88Q has no problem at all paying its short term obligations.
88Q has a better Quick ratio (11.15) than 95.18% of its industry peers.
Industry RankSector Rank
Current Ratio 11.36
Quick Ratio 11.15
88Q.DE Yearly Current Assets VS Current Liabilites88Q.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

7

3. Growth

3.1 Past

The earnings per share for 88Q have decreased strongly by -26.52% in the last year.
88Q shows a strong growth in Revenue. In the last year, the Revenue has grown by 198.49%.
88Q shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 35.80% yearly.
EPS 1Y (TTM)-26.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.8%
Revenue 1Y (TTM)198.49%
Revenue growth 3Y40.28%
Revenue growth 5Y35.8%
Sales Q2Q%257.93%

3.2 Future

88Q is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.34% yearly.
The Revenue is expected to grow by 97.36% on average over the next years. This is a very strong growth
EPS Next Y-34.32%
EPS Next 2Y-7.14%
EPS Next 3Y2.5%
EPS Next 5Y10.34%
Revenue Next Year50%
Revenue Next 2Y141.52%
Revenue Next 3Y132.08%
Revenue Next 5Y97.36%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
88Q.DE Yearly Revenue VS Estimates88Q.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 10M 20M 30M 40M
88Q.DE Yearly EPS VS Estimates88Q.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

88Q reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year 88Q is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
88Q.DE Price Earnings VS Forward Price Earnings88Q.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
88Q.DE Per share data88Q.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-7.14%
EPS Next 3Y2.5%

More info and screens

0

5. Dividend

5.1 Amount

88Q does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

4BASEBIO PLC

FRA:88Q (12/18/2025, 7:00:00 PM)

7

-0.2 (-2.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-23 2024-09-23
Earnings (Next)N/A N/A
Inst Owners13.48%
Inst Owner ChangeN/A
Ins Owners10.92%
Ins Owner ChangeN/A
Market Cap108.78M
Revenue(TTM)1.78M
Net Income(TTM)-14.41M
Analysts84.44
Price Target20.21 (188.71%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.63%
PT rev (3m)0.15%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-122.11%
EPS NY rev (3m)-122.11%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-34.56%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 53.48
P/FCF N/A
P/OCF N/A
P/B 5.01
P/tB 6.26
EV/EBITDA N/A
EPS(TTM)-1.13
EYN/A
EPS(NY)-1.14
Fwd EYN/A
FCF(TTM)-1.12
FCFYN/A
OCF(TTM)-1.01
OCFYN/A
SpS0.13
BVpS1.4
TBVpS1.12
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -39.08%
ROE -75.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 61.55%
FCFM N/A
ROA(3y)-45.31%
ROA(5y)-32.39%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.33%
GM growth 5YN/A
F-Score4
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0.81
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 152.56%
Cap/Sales 85.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.36
Quick Ratio 11.15
Altman-Z 1.58
F-Score4
WACC8.39%
ROIC/WACCN/A
Cap/Depr(3y)276.3%
Cap/Depr(5y)321.58%
Cap/Sales(3y)395.7%
Cap/Sales(5y)363.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-26.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.8%
EPS Next Y-34.32%
EPS Next 2Y-7.14%
EPS Next 3Y2.5%
EPS Next 5Y10.34%
Revenue 1Y (TTM)198.49%
Revenue growth 3Y40.28%
Revenue growth 5Y35.8%
Sales Q2Q%257.93%
Revenue Next Year50%
Revenue Next 2Y141.52%
Revenue Next 3Y132.08%
Revenue Next 5Y97.36%
EBIT growth 1Y-44.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-37.55%
EBIT Next 3Y6.42%
EBIT Next 5Y15.28%
FCF growth 1Y-134.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-163.49%
OCF growth 3YN/A
OCF growth 5YN/A

4BASEBIO PLC / 88Q.DE FAQ

Can you provide the ChartMill fundamental rating for 4BASEBIO PLC?

ChartMill assigns a fundamental rating of 3 / 10 to 88Q.DE.


What is the valuation status for 88Q stock?

ChartMill assigns a valuation rating of 0 / 10 to 4BASEBIO PLC (88Q.DE). This can be considered as Overvalued.


How profitable is 4BASEBIO PLC (88Q.DE) stock?

4BASEBIO PLC (88Q.DE) has a profitability rating of 1 / 10.


How financially healthy is 4BASEBIO PLC?

The financial health rating of 4BASEBIO PLC (88Q.DE) is 5 / 10.